CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Setmelanotidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04725240
NCT04725240Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc.·interventional·Posted Jan 26, 2021·Updated Feb 7, 2025

In Brief

A Phase 2 clinical trial evaluating Setmelanotide for Hypothalamic Obesity. Completed, enrolled 18 participants across 5 sites.

Detailed Summary

Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypothalamic Obesity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 26, 2021
Enrollment StartJun 7, 2021
Primary CompletionJun 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.4 years ago

Interventions

Setmelanotidedrug

Setmelanotide for SC injection